Pharmacology, Toxicology and Pharmaceutical Science
Mycobacterium Tuberculosis
100%
Lung Tuberculosis
93%
Lung Cancer
56%
Tuberculostatic Agent
47%
Multi-Drug-Resistant Tuberculosis
45%
Epidermal Growth Factor Receptor
38%
Isoniazid
37%
Drug Resistance
35%
Chemotherapy
31%
Lung Adenocarcinoma
31%
Thrombin
30%
Prevalence
28%
Atypical Mycobacterium
27%
Connective Tissue Growth Factor
25%
Ethambutol
25%
Cohort Study
24%
Nuclear Factor
22%
Alternative Complement Pathway C3 C5 Convertase
22%
Drug Resistant Tuberculosis
22%
Nucleic Acid
18%
Rifampicin
18%
Tuberculosis
18%
Chronic Obstructive Lung Disease
17%
Ofloxacin
17%
Non Small Cell Lung Cancer
16%
Infection
16%
Quinolone Derivative
16%
Pyrazinamide
15%
Transcription Factor AP 1
15%
Nephrotoxicity
15%
Hepatotoxicity
15%
Liver Disease
15%
Mitogen Activated Protein Kinase
15%
Uridine Diphosphate
15%
Comorbidity
14%
Disease
12%
HIV
11%
Recurrence Risk
11%
Inducible Nitric Oxide Synthase
11%
Phosphotransferase
11%
Overall Survival
11%
Prothionamide
11%
Isoniazid Plus Rifampicin
10%
Pharmacokinetics
10%
Mycobacterium Bovis BCG
9%
Diabetes Mellitus
9%
Chronic Disease
9%
Binding Site
9%
Cisplatin
9%
Recurrent Disease
8%
Medicine and Dentistry
Lung Tuberculosis
91%
Multidrug Resistant Tuberculosis
90%
Mycobacterium Tuberculosis
53%
Lung Cancer
40%
Tuberculosis Treatment
31%
Prevalence
31%
Nucleic Acid Amplification
30%
Isoniazid
26%
Epidermal Growth Factor Receptor
25%
Drug Resistant Tuberculosis
25%
Atypical Mycobacterium
25%
Infection
23%
Tuberculosis
23%
Sputum
22%
Drug Sensitivity
21%
Drug Resistance
19%
Rifampicin
19%
Disease
19%
Hemoptysis
18%
Chest Radiograph
17%
Ofloxacin
17%
Ethambutol
17%
Mortality Rate
16%
Cohort Analysis
16%
Lung Adenocarcinoma
16%
Short Course Therapy
15%
Personalized Medicine
15%
Hazard Ratio
15%
Pneumonectomy
15%
Intensive Care Unit
15%
Observational Study
15%
Nephrotoxicity
15%
Extrapulmonary Tuberculosis
15%
Sputum Culture
14%
Surgery
12%
Chronic Obstructive Pulmonary Disease
12%
In Vitro
11%
Patient Characteristics
11%
Sputum Smear
10%
Directly Observed Therapy
10%
Retrospective Cohort Study
10%
Sputum Examination
9%
Cancer Cell
9%
Protionamide
9%
Rifabutin
9%
Fistula
9%
Non Small Cell Lung Cancer
9%
Pyrazinamide
9%
Cisplatin
8%
Chronic Disease
8%
Nursing and Health Professions
Lung Tuberculosis
52%
Multi-Drug-Resistant Tuberculosis
37%
Cohort Analysis
24%
Lung Cancer
22%
Prevalence
19%
Confidence Interval
19%
Nucleic Acid Amplification
15%
Treatment Outcome
15%
Tuberculosis Control
14%
Intensive Care Unit
13%
Disease
13%
Disease Control
12%
Infection
12%
Symptom
10%
Odds Ratio
9%
Thorax Radiography
9%
Epidermal Growth Factor Receptor
8%
Tuberculostatic Agent
8%
Quinolone Derivative
8%
Age Distribution
8%
Isoniazid
8%
Hazard Ratio
7%
Lung Function Test
7%
Population
7%
Mortality Rate
7%
Psychological Distress Assessment
7%
Human Immunodeficiency Virus Infection
7%
Distress Syndrome
7%
Asthma Control Test
7%
Chronic Disease
7%
Dual Energy X Ray Absorptiometry
7%
Electrocardiogram
7%
Foreign Born
7%
Physical Disease by Body Function
7%
Six Minute Walk Test
7%
Treatment Interruption
7%
Lung Infection
7%
Elderly Patient
7%
Extrapulmonary Tuberculosis
7%
Medical Intensive Care Unit
7%
Short Course Therapy
7%
Uridine Diphosphate
7%
Early Diagnosis
7%
Lung Resection
7%
QT Prolongation
7%
Carboplatin
7%
Cisplatin
7%
Case-Control Study
7%
Sputum Smear
7%
Nephrotoxicity
7%
